Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
暂无分享,去创建一个
T. Shelekhova | N. Medvedeva | V. V. Ryabchikova | E. Karyagina | E. Baumert | K. Kaplanov | I. Skorokhod | D. Ptashnikov | A. Luchinin | V. Potapenko | S. Moiseev | S. Povzun | M. Shirokova | A. Levanov | A. Nizamutdinova | N. Dorofeeva | A. A. Bobrova | R. V. Vashchenkov | A. V. Novitskiĭ | О. V. Pirogova | М. V. Platonov | V. Porunova | S. Y. Simeniv | Е. А. Ukrainchenko | D. А. Chaginskaya | A. A. Shutylev
[1] O. Trofimova,et al. Features of management of oncohematological patients in the context of the COVID-19 pandemic , 2020 .
[2] M. Dimopoulos,et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. , 2020, Blood.
[3] M. Dimopoulos,et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse , 2020, Leukemia.
[4] Gordon Cook,et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) , 2020, Leukemia.
[5] Kihyun Kim,et al. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study) , 2020, American journal of hematology.
[6] O. Decaux,et al. Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma , 2019, Blood.
[7] H. Asaoku,et al. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network , 2019, Blood Cancer Journal.
[8] S. Lonial,et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients , 2019, Cancer.
[9] L. Escoda,et al. Pomalidomide‐dexamethasone for treatment of soft‐tissue plasmacytomas in patients with relapsed / refractory multiple myeloma , 2019, European journal of haematology.
[10] T. Spektor,et al. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study , 2018, European journal of haematology.
[11] С. В. Семочкин,et al. ЭПИДЕМИОЛОГИЯ МНОЖЕСТВЕННОЙ МИЕЛОМЫ ПО ДАННЫМ АНАЛИЗА ПОПУЛЯЦИОННОГО РЕГИСТРА КИРОВСКОЙ ОБЛАСТИ , 2017 .
[12] L. Mendeleeva,et al. Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma , 2017 .
[13] H. Goldschmidt,et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] H. Goldschmidt,et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. , 2016, Blood.
[15] S. Jagannath,et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. , 2016, Blood.
[16] E. Dı́az-Rodrı́guez,et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone , 2014, Leukemia.
[17] M. Boccadoro,et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. , 2013, Blood.
[18] N. Munshi,et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. , 2013, Blood.
[19] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[20] A. Dispenzieri,et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma , 2011, Leukemia.
[21] P. L. Bergsagel,et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. , 2010, Blood.
[22] M. Smyth,et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma , 2010, Leukemia.
[23] N. Perevodchikova,et al. CLINICAL EXPERIENCES WITH SARCOLYSIN IN NEOPLASTIC DISEASES , 1958, Annals of the New York Academy of Sciences.